GRABS-0NCT06162715
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 14 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Final enrollment: 33 participants (planned 30)
- Notable Eligibility criteria expanded, about 29 words
- Primary completion date changed from estimate of Jan 1, 2027 to Oct 10, 2026
- Study completion moved earlier from Dec 1, 2027 to Apr 30, 2027
- Publications: details revised at 1 of 1 entry
- Minor Trial status changed: Enrolling by Invitation → Active, Not Recruitingv16
- Notable Primary endpoint(s) modified
- Secondary endpoints: 4 to 3
- Notable Eligibility criteria revised
- Primary completion moved earlier from May 2027 to Jan 1, 2027
- Study completion date: Dec 2027 to Dec 1, 2027
- Secondary endpoints: details revised at 2 of 4 entries
Show 8 earlier versionsHide 8 earlier versions
- Minor Primary completion date: Jan 2027 to May 2027v12
- Minor Study description expanded, about 20 wordsv11
- Minor Start date changed from estimate of Nov 1, 2024 to Oct 30, 2024v8
- Notable Start date: Oct 1, 2024 to Nov 1, 2024v7
- Notable Trial status: Not Yet Recruiting to Enrolling by Invitationv6
- Notable Phase: Phase 2 to Phase 2/3
- Secondary endpoints: 3 to 4
- Study title revised
Notable Phase: Phase 2/3 to Phase 2v3 Show 9 more changesShow less
- Enrollment target: 45 to 30
- Primary completion date: Aug 2025 to Jan 2027
- Start date: May 2024 to Oct 1, 2024
- Eligibility criteria expanded, about 24 words
- Primary endpoints: 2 to 1
- Study completion date: Jan 2026 to Dec 2027
- Interventions: Placebo (Drug), Tirzepatide (Drug) to Standard of Care post-gastric bypass (Other), Tirzepatide (Drug)
- Secondary endpoints: 1 to 3
- Study description expanded, about 322 words
- Notable Eligibility criteria shortened, about 33 words
- Interventions: Tirzepatide (Drug) to Placebo (Drug), Tirzepatide (Drug)
- Secondary endpoints expanded, about 5 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants in the TRZ cohort will initiate a standardized dose titration as described in the package insert. Participants will begin TRZ at 2.5 mg for four weeks and then increase by 2.5 mg every 4 weeks to a maximum dose of 15 mg. If subjects experience intolerable GI symptoms, they will be allowed to decrease to a lower dose by 2.5 mg for 2 weeks, at which point another attempt at an increased dose will be trialed. Should patients not tolerate a higher dose a second time, they will have the dose again lowered by 2.5 mg and kept at the lower dose for the remainder of the study, except for patients who do not tolerate two attempts at 5 mg. For patients who fail to titrate to at least 5 mg TRZ, a third attempt at an increased dose will be attempted 4 weeks after the second decrease in dose. These patients will then remain on 5 mg for the remainder of the intervention period. All participants receiving TRZ will be pooled in terms of outcomes measures.
Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook for 24 weeks. After 24 weeks, particiapnts in the control arm will crossover to the Tirzepatide arm and receive 24 weeks of TRZ following the same titration.
Drugs: Tirzepatide
Other: Standard of Care post-gastric bypass
Sites
1 site in 1 country
- Vanderbilt University Medical CenterNashville, Tennessee, United States